AstraZeneca (AZN) Tops Q1 EPS by 20c

AstraZeneca (NASDAQ: AZN) reported Q1 EPS of $1.92, $0.20 better than the analyst estimate of $1.72. Revenue for the quarter came in at $10.88 billion versus the consensus estimate of $10.69 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
• Lonza Group (LONN:SW) (LZAGY) PT Raised to CHF720 at RBC Capital
• DraftKings Inc. (DKNG) PT Raised to $36 at Citizens on Prediction Market Opportunity